Effects of pycnogenol on cardiometabolic health: A systematic review and meta-analysis of randomized controlled trials

Aim Clinical trials on the effect of pycnogenol supplementation on cardiometabolic health have been controversial. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the potential effect of pycnogenol supplementation on cardiometabolic profile. Methods PubMed, Scopus, and ISI Web of Science databases were searched until October 2018. RCTs that evaluated the effects of pycnogenol on cardiometabolic parameters were included. DerSimonian and Laird random-effect models were used to compute the weighted mean differences (WMDs) and 95% confidence intervals (CIs). Results Twenty-four RCTs including 1594 participants were included in the meta-analysis. Pycnogenol significantly reduced fasting blood glucose (WMD: −5.86 mg/dl; 95% CI: −9.56, −2.15), glycated hemoglobin (WMD = −0.29%, 95%CI: −0.56, −0.01), systolic blood pressure (WMD: −2.54 mmhg; 95% CI: −4.08, -0.99), diastolic blood pressure (WMD: −1.76 mmhg; 95% CI: −3.12, −0.41), body mass index (WMD: −0.47 kg/m2; 95% CI: −0.90, −0.03), LDL cholesterol (WMD: −7.12 mg/dl; 95% CI: −13.66, −0.58) and increased HDL cholesterol (WMD: 3.27 mg/dl; 95% CI: 0.87, 5.66). Conclusion This meta-analysis suggests that pycnogenol may have a role in preventing cardiometabolic disease. However, further well-designed RCTs are recommended to evaluate its long-term effects and explore the optimal duration of use and dosage.